The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Analyst Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $994.00. Discover top-rated stocks from highly ranked analysts ...
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...
1don MSN
We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...
The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback